Source: Immunity. Unidades: FMRP, FCFRP, FCF, ICB, BIOINFORMÁTICA
Subjects: ADENOSINA, FÁRMACOS IMUNOSSUPRESSORES, SEPSE, CAMUNDONGOS, INTERLEUCINA 10, MACRÓFAGOS
ABNT
NASCIMENTO, Daniele Carvalho et al. Sepsis expands a CD39 + plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. Immunity, v. 54, n. 9, p. 2024-2041, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.immuni.2021.08.005. Acesso em: 30 ago. 2024.APA
Nascimento, D. C., Viacava, P. R., Ferreira, R. G., Damaceno, M. A., Piñeros, A. R. A., Melo, P. H. de, et al. (2021). Sepsis expands a CD39 + plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity. Immunity, 54( 9), 2024-2041. doi:10.1016/j.immuni.2021.08.005NLM
Nascimento DC, Viacava PR, Ferreira RG, Damaceno MA, Piñeros ARA, Melo PH de, Donate PB, Toller-Kawahisa JE, Zoppi D, Veras FP, Peres RS, Silva LM, Caetité D, Oliveira AER, Castro IMS, Kauffenstein G, Nakaya HTI, Borges M de C, Zamboni DS, Fonseca DM da, Paschoal JAR, Cunha TM, Quesniaux V, Linden J, Cunha FQ, Ryffe B, Alves-Filho JC. Sepsis expands a CD39 + plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity [Internet]. Immunity. 2021 ; 54( 9): 2024-2041.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/j.immuni.2021.08.005Vancouver
Nascimento DC, Viacava PR, Ferreira RG, Damaceno MA, Piñeros ARA, Melo PH de, Donate PB, Toller-Kawahisa JE, Zoppi D, Veras FP, Peres RS, Silva LM, Caetité D, Oliveira AER, Castro IMS, Kauffenstein G, Nakaya HTI, Borges M de C, Zamboni DS, Fonseca DM da, Paschoal JAR, Cunha TM, Quesniaux V, Linden J, Cunha FQ, Ryffe B, Alves-Filho JC. Sepsis expands a CD39 + plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity [Internet]. Immunity. 2021 ; 54( 9): 2024-2041.[citado 2024 ago. 30 ] Available from: https://doi.org/10.1016/j.immuni.2021.08.005